Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients

Annals of Surgical Oncology

Volumn 19, Issue 10, 2012, Pages 3257-3263

  Nguyen, Bichlien ^a   Cusumano, Pino G ^b   Deck, Kenneth ^c   Kerlin, Deborah ^d   Garcia, Agustin A ^e   Barone, Julie L ^f   Rivera, Edgardo ^g   Yao, Katharine ^h   De Snoo, Femke A ⁱ   Van Den Akker, Jeroen ⁱ   Stork Sloots, Lisette ⁱ   Generali, Daniele ^j  

^a LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^b CHC   (Belgium)

^c Memorial Care   (United States)

^d John Muir ^*  (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f SHARP MEMORIAL HOSPITAL   (United States)

^g HOUSTON METHODIST HOSPITAL   (United States)

^h NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

ⁱ Agendia NV   (Netherlands)

^j UOM Patologia Mammaria Laboratorio di Oncologia Molecolare Senologica   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; RNA;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL LABORATORY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PATHOLOGIST;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84868135433     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2561-6     Document Type: Article

References (15)

1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
2. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, 2011. Ann Oncol. 2011;22:1736-47.
3. Arihiro K, Umemura S, Kurosumi M, et al. Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays. Am J Clin Pathol. 2007;127:356-65. (Pubitemid 46806328)
4. Oyama T, Ishikawa Y, Hayashi M, Arihiro K, Horiguchi J. The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer. Breast Cancer. 2007;14:182-8.
5. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7(5):e1000279.
6. Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16:5222-32.
7. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790-800.
8. Krijgsman O, Roepman P, Zwart W, et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat. 2012;133:37-47.
9. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer, 2009. Ann Oncol. 2009;20:1319-29.
10. Roepman P, Horlings HM, Krijgsman O, et al. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res. 2009; 15:7003-11.
11. Wesseling J, Cusumano G, Tinterri C, et al. High concordance for microarray based determination of ER, PR and HER2 receptor status and local IHC/FISH assessment worldwide in 827 patients (abstract P5-11-09). Cancer Res. 2011;71(24 Suppl.):543 s.
12. Viale G, Bogaerts J, Slaets L, et al. High concordance of protein (by IHC), gene (by FISH; HER2 only) and microarray readout (by TargetPrint) of ER/PR/HER2: results from the MINDACT trial (abstract P1-07-06). Cancer Res. 2011;71(24 Suppl.):190 s.
13. Glas AM, Floore A, Delahaye LJ, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics. 2006;7:278.
14. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736-50.
15. Gevensleben H, Göhring UJ, Büttner R, et al. Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer. Int J Mol Med. 2010;26:837-43.